Needham Maintains Buy on Conmed, Lowers Price Target to $119
Portfolio Pulse from Benzinga Newsdesk
Needham analyst Mike Matson has maintained a 'Buy' rating on Conmed (NYSE:CNMD) but lowered the price target from $140 to $119.

October 26, 2023 | 9:33 am
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Needham analyst has maintained a 'Buy' rating on Conmed but lowered the price target from $140 to $119.
The news is directly about Conmed and is likely to impact its stock. While the 'Buy' rating is maintained, the lowering of the price target might create some uncertainty among investors, potentially affecting the stock's short-term performance.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100